921 CIRCULATING TUMOR CELLS IN NON-MUSCLE INVASIVE BLADDER CANCER AND THEIR PROGNOSTIC VALUE: A CELLSEARCH ANALYSISстатья из журнала
Аннотация: You have accessJournal of UrologyBladder Cancer: Basic Research (II)1 Apr 2013921 CIRCULATING TUMOR CELLS IN NON-MUSCLE INVASIVE BLADDER CANCER AND THEIR PROGNOSTIC VALUE: A CELLSEARCH ANALYSIS Gian Maria Busetto, Paola Gazzaniga, Chiara Nicolazzo, Arianna Petracca, Riccardo Giovannone, Vincenzo Gentile, and Ettore De Berardinis Gian Maria BusettoGian Maria Busetto Rome, Italy More articles by this author , Paola GazzanigaPaola Gazzaniga Rome, Italy More articles by this author , Chiara NicolazzoChiara Nicolazzo Rome, Italy More articles by this author , Arianna PetraccaArianna Petracca Rome, Italy More articles by this author , Riccardo GiovannoneRiccardo Giovannone Rome, Italy More articles by this author , Vincenzo GentileVincenzo Gentile Rome, Italy More articles by this author , and Ettore De BerardinisEttore De Berardinis Rome, Italy More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2013.02.498AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Although most cases of bladder cancer patients present with a disease that is confined to mucosa (Ta) or submucosa (T1), recurrence and progression rate in this cohort of patients is high. Circulating tumor cells (CTCs) enumeration through Cell Search system (Veridex) is widely used. Recent studies have shown that CTCs are released in circulation in a very early phase of cancer disease where their presence is associated with a worse prognosis of patients and CTC count could reflect the ongoing progression of cancer disease. METHODS Primary endpoint of the present study was to investigate the prognostic significance of CTCs in NMIBC patients; to this purpose the presence of CTCs has been used to predict time to first recurrence (TFR) and time to progression (TTP) in a follow up of 24 months. Secondary endpoints were the association between CTC presence and known prognostic variables such as T, G and presence of CIS. In a prospective study, 65 patients were enrolled all with histopathological diagnosis of NMIBC. Patients characheristics: 26/65 (40%) Ta, 39/65 (60%) T1, 11/65 (17%) G1, 15/65 (23%), 39/65 (60%) G3 13/65 (20%) Cis associated. Blood drawings were carried out in all patients at the first diagnosis, 1h before TURB. Patients were included in a follow-up programme which consisted of cystoscopy and urinary cytology every 3 months and a URO-CT every 12 months. CellSearch system (Veridex) was used for CTCs enumeration. Briefly, the method is an immunomagnetic cell enrichment which uses antibodies targeting epithelial cell adhesion molecule (EpCAM) and nucleus labeling with fluorescent dye. RESULTS CTC were detectable in 11/65 patients (17%), and in 0/30 healthy volunteers. CTC were found in 11/39 (28%) patients with T1 tumors, and in 0/18 patients with Ta (p>0.02). CTC presence was also found associated to concomitant presence of CIS; in the group of patients with CIS, CTC were found in 8/13 (61.5%) compared to 3/52 (5.7%) found in the group without CIS (p>= 0.01). For what concern TTP, of the 8 CTC+ patients, 9 experienced the event within the end of follow-up, with a median TTP of 12 months. No events were observed in the 44 CTC- patients (p<0.001). For what concern TFR, there were once again 10 events in the CTC+ group within end of follow-up, with a median TFR of 11 months and 18 events in the CTC- group. CONCLUSIONS Evaluation of CTC could provide a non-invasive source of representative tumor material; although the prognostic significance has been validated in metastatic setting, a growing body of evidence is now demonstrating their role in early staged tumors as well. © 2013 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 189Issue 4SApril 2013Page: e378-e379 Advertisement Copyright & Permissions© 2013 by American Urological Association Education and Research, Inc.Metrics Author Information Gian Maria Busetto Rome, Italy More articles by this author Paola Gazzaniga Rome, Italy More articles by this author Chiara Nicolazzo Rome, Italy More articles by this author Arianna Petracca Rome, Italy More articles by this author Riccardo Giovannone Rome, Italy More articles by this author Vincenzo Gentile Rome, Italy More articles by this author Ettore De Berardinis Rome, Italy More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...
Год издания: 2013
Авторы: Gian Maria Busetto, Paola Gazzaniga, Chiara Nicolazzo, Arianna Petracca, Riccardo Giovannone, Vincenzo Gentile, Ettore De Berardinis
Издательство: Lippincott Williams & Wilkins
Источник: The Journal of Urology
Ключевые слова: Cancer Cells and Metastasis, Bladder and Urothelial Cancer Treatments, Tissue Engineering and Regenerative Medicine
Открытый доступ: closed
Том: 189
Выпуск: 4S